Beijing Luzhu Biotechnology Co Ltd
HKEX:2480
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Beijing Luzhu Biotechnology Co Ltd
HKEX:2480
|
CN |
|
J
|
JCR Pharmaceuticals Co Ltd
TSE:4552
|
JP |
|
Deutsche Telekom AG
XETRA:DTE
|
DE |
|
Silk Logistics Holdings Ltd
ASX:SLH
|
AU |
|
GPI SpA
MIL:GPI
|
IT |
|
KEI Industries Ltd
NSE:KEI
|
IN |
|
Integrated Industries Ltd
BSE:531889
|
IN |
Beijing Luzhu Biotechnology Co Ltd
Beijing Luzhu Biotechnology Co., Ltd. engages in the development, production, and sale of active pharmaceutical ingredients. The company is headquartered in Beijing, Beijing. The company went IPO on 2023-05-08. The firm is also engaged in out-licensing human vaccines and therapeutic biologics. Its products under clinical development include recombinant herpes zoster vaccine LZ901, and antibody injection products K3 and K193. Its LZ901 is mainly used to prevent herpes zoster caused by varicella zoster virus in adults aged 50 and above. The firm operates in the domestic market and overseas markets.
Beijing Luzhu Biotechnology Co., Ltd. engages in the development, production, and sale of active pharmaceutical ingredients. The company is headquartered in Beijing, Beijing. The company went IPO on 2023-05-08. The firm is also engaged in out-licensing human vaccines and therapeutic biologics. Its products under clinical development include recombinant herpes zoster vaccine LZ901, and antibody injection products K3 and K193. Its LZ901 is mainly used to prevent herpes zoster caused by varicella zoster virus in adults aged 50 and above. The firm operates in the domestic market and overseas markets.
